 Mesoblast Limited NASDAQ: MESO has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderatesevere acute respiratory distress syndrome ARDS, which had been halted after the third interim analysis, as previously announced. The trial enrolled 222 mechanically ventilated COVID-19 patients. 